Rokan (r) Novo 120 mg ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
18脊髄小脳変性症(多系統萎縮症を除く。)1

18. 脊髄小脳変性症(多系統萎縮症を除く。)


臨床試験数 : 76 薬物数 : 98 - (DrugBank : 31) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 65
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-005371-34-FR
(EUCTR)
18/03/200820/12/2007EFFICACY OF EGb 761® 120 mg bid VERSUS PLACEBO IN PATIENTS SUFFERING FROM FRIEDREICH ATAXIAA 3 months, phase II, randomised, double blind, placebo-controlled, parallel groups, clinical study. - EGB 761 in FRIEDREICH ATAXIAEFFICACY OF EGb 761® 120 mg bid VERSUS PLACEBO IN PATIENTS SUFFERING FROM FRIEDREICH ATAXIAA 3 months, phase II, randomised, double blind, placebo-controlled, parallel groups, clinical study. - EGB 761 in FRIEDREICH ATAXIA Out patient suffering from friedreich ataxia aged from 12 to 20 yearsTrade Name: Rokan (r) Novo 120 mg
Product Name: EGB 761 (r) 120 mg
INN or Proposed INN: Standardized Ginkgo Biloba Extract (EGb 761 (r)
BEAUFOUR IPSEN PHARMANULLNot RecruitingFemale: yes
Male: yes
20Phase 2France